Atopic Dermatitis | Dermira | DRM06-AD 17
Pharmaceutical Company/Sponsor:
Dermira
Code:
DRM06-AD 17
Title:
An Open-Label, Single-Arm Study to Assess the Safety and Efficacy of Lebrikizumab in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis
Type:
Interventional
Phase:
3
Condition/Disease:
Atopic Dermatitis
Intervention(s)/Treatment(s):
Biological: Lebrikizumab
Status:
Recruiting
Link for Additional Information:
